JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265387

Human LITAF knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

LITAF KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2.

View Alternative Names

CMT1C, FLJ38636, LITAF_HUMAN, LPS-induced TNF-alpha factor, Lipopolysaccharide induced TNF alpha factor, Lipopolysaccharide induced TNF factor, Lipopolysaccharide-induced tumor necrosis factor-alpha factor, MGC116698, MGC116700, MGC116701, MGC125274, MGC125275, MGC125276, PIG 7, SIMPLE, Small integral membrane protein of lysosome/late endosome, TP53I7, Tumor protein p53 inducible protein 7, p53-induced gene 7 protein

1 Images
Sanger Sequencing - Human LITAF knockout HeLa cell line (AB265387)
  • Sanger seq

Unknown

Sanger Sequencing - Human LITAF knockout HeLa cell line (AB265387)

Homozygous : Insertion of the selection cassette in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265387-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265387 Human LITAF knockout HeLa cell line", "number":"AB265387-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265387-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265387 Human LITAF knockout HeLa cell line", "number":"AB265387-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
LITAF
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The LITAF protein also known as Lipopolysaccharide-induced TNF factor plays an important mechanical role in cellular function. It has a molecular mass of approximately 18 kDa and is prevalent in various tissues particularly within the immune system. LITAF influences the process of ubiquitination by interacting with other proteins which impacts cellular response to external stimuli. The protein contains a conserved region that facilitates interaction with ubiquitin ligases and also plays a role in the degradation of misfolded proteins.
Biological function summary

The function of LITAF extends to the regulation of inflammation. This protein acts by modulating the transcription of pro-inflammatory cytokines including TNF-alpha. As part of complexes LITAF may work in collaboration with other molecules to regulate these inflammatory responses. This regulation is vital for maintaining balance within immune responses playing a significant part in defending against hostile pathogens while avoiding excessive tissue damage caused by inflammation.

Pathways

The immune and inflammatory responses prominently feature the LITAF protein. It plays a role in the TNF signaling pathway where it helps regulate the expression of tumor necrosis factor and other inflammatory mediators. LITAF is closely related to molecules like TRAF and NF-kB within these pathways facilitating various immune functions and responses. These interactions are essential for correct signaling and action during immune challenges.

Researchers have linked LITAF to conditions such as Charcot-Marie-Tooth disease and inflammatory bowel disease. The protein's involvement with TNF-alpha links it to chronic inflammation contributing to the pathogenesis of these disorders. Studies suggest that dysregulation or mutations in LITAF may affect the normal inflammatory response further connecting with proteins such as NF-kB to exacerbate symptoms of these diseases. Understanding LITAF's role in these conditions could help in developing therapeutic strategies to manage such disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com